phospholipid Scramblase 3 (PLSCR3) (Middle Region) Peptid
PLSCR3
Reaktivität: Human
Wirt: Synthetic
BP, WB
-
- Target Alle PLSCR3 Produkte
- PLSCR3 (phospholipid Scramblase 3 (PLSCR3))
- Protein Region
- Middle Region
- Spezies
- Human
-
Quelle
- Synthetic
- Applikation
- Blocking Peptide (BP), Western Blotting (WB)
- Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-PLSCR3 antibody (Catalog #: ARP57395_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Aufreinigung
- Purified
-
-
- Applikationshinweise
- Each Investigator should determine their own optimal working dilution for specific applications.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Konzentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handhabung
- Avoid repeated freeze-thaw cycles.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- PLSCR3 (phospholipid Scramblase 3 (PLSCR3))
- Synonyme
- 2210403O21Rik Peptide, 2610037N06Rik Peptide, ESTM3 Peptide, X83310 Peptide, Pls3 Peptide, zgc:77051 Peptide, phospholipid scramblase 3 Peptide, phospholipid scramblase 3b Peptide, PLSCR3 Peptide, Plscr3 Peptide, plscr3b Peptide
- Hintergrund
-
PLSCR3 may mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane.PLSCR3 may play a central role in the initiation of fibr
Alias Symbols: -
Protein Interaction Partner: PLSCR1,PRKCD,TRIP13,PLSCR1,PRKCD,TRIP13
Protein Size: 295 - Molekulargewicht
- 32 kDa
- Gen-ID
- 57048
- NCBI Accession
- NM_020360, NP_065093
- UniProt
- Q9NRY6
-
Sie sind hier:
